SD Plasma in TTP and coagulation factor deficiencies for which no concentrates are available

Area of Science:

• Hematology
• Plasma-derived therapies
• Coagulation disorders

Background:

• Thrombotic thrombocytopenic purpura (TTP) is a life-threatening condition.
• Congenital deficiencies in coagulation factors require effective replacement therapies.
• Solvent/detergent plasma (SDP) is a pathogen-inactivated plasma product.

Purpose of the Study:

• To evaluate the efficacy and safety of SDP in treating TTP.
• To assess SDP's utility in replacing coagulation factors for various deficiencies.
• To compare SDP with fresh frozen plasma (FFP) in acute TTP treatment.

Main Methods:

• Infusion of SDP in 6 patients with chronic relapsing TTP (CRTTP).
• Controlled study comparing SDP (16 patients) with FFP (10 patients) in acute TTP.
• Administration of SDP to 48 patients with congenital coagulation factor deficiencies for surgical prophylaxis, bleeding, and routine prophylaxis.

Main Results:

• In CRTTP patients, SDP infusion led to increased platelet counts and decreased LDH levels, with stable hemoglobin and good health outcomes.
• In acute TTP, no significant differences were observed between SDP and FFP groups regarding survival, relapse rates, treatment resistance, or treatment volume.
• SDP administration in factor-deficient patients achieved target factor levels, with physicians reporting successful bleeding control.

Conclusions:

• SDP is an effective therapeutic option for both acute and chronic relapsing TTP.
• SDP is a viable alternative to FFP for TTP treatment, offering comparable outcomes.
• SDP successfully replaces coagulation factors in patients with congenital deficiencies, aiding in bleeding management.